CABG in ischemic cardiomyopathy
-
Upload
daych -
Category
Health & Medicine
-
view
920 -
download
1
Transcript of CABG in ischemic cardiomyopathy
![Page 1: CABG in ischemic cardiomyopathy](https://reader034.fdocuments.in/reader034/viewer/2022052316/559426a71a28ab1f768b47a6/html5/thumbnails/1.jpg)
Ischemic Cardiomyopathy
![Page 2: CABG in ischemic cardiomyopathy](https://reader034.fdocuments.in/reader034/viewer/2022052316/559426a71a28ab1f768b47a6/html5/thumbnails/2.jpg)
Ischemic Cardiomyopathy
“The most common cause of heart failure in developed countries.”
He J, Ogden LG, Bazzano LA, et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001; 161:996.
![Page 3: CABG in ischemic cardiomyopathy](https://reader034.fdocuments.in/reader034/viewer/2022052316/559426a71a28ab1f768b47a6/html5/thumbnails/3.jpg)
Definition of Ischemic Cardiomyopathy
“Impairment of left ventricular function that results from coronary artery disease”
![Page 4: CABG in ischemic cardiomyopathy](https://reader034.fdocuments.in/reader034/viewer/2022052316/559426a71a28ab1f768b47a6/html5/thumbnails/4.jpg)
Pathogenesis
Irreversible loss of myocardium from prior MI with ventricular remodeling
AND
Partially reversible loss of contractility due to reduced function of ischemic but still viable myocardium (Hibernating Myocardium)
![Page 5: CABG in ischemic cardiomyopathy](https://reader034.fdocuments.in/reader034/viewer/2022052316/559426a71a28ab1f768b47a6/html5/thumbnails/5.jpg)
Hibernating Myocardium
“Contractile dysfunction in viable myocardium that improves after revascularization or perhapmedical therapy”
Chareonthaitawee P, Gersh BJ, Araoz PA, Gibbons RJ. J Am Coll Cardiol. 2005 Aug 16;46(4):567-74.
![Page 6: CABG in ischemic cardiomyopathy](https://reader034.fdocuments.in/reader034/viewer/2022052316/559426a71a28ab1f768b47a6/html5/thumbnails/6.jpg)
http://www.britannica.com/blogs/wp-content/uploads/2011/05/dormouse.jpg
![Page 7: CABG in ischemic cardiomyopathy](https://reader034.fdocuments.in/reader034/viewer/2022052316/559426a71a28ab1f768b47a6/html5/thumbnails/7.jpg)
“No randomized trials of revascularization in patients with coronary artery disease with decrease LVEF”
“Multiple observational study suggesting improvement in outcome with CABG”
![Page 8: CABG in ischemic cardiomyopathy](https://reader034.fdocuments.in/reader034/viewer/2022052316/559426a71a28ab1f768b47a6/html5/thumbnails/8.jpg)
Current Recommendation for CABG in patient with poor LV function
![Page 9: CABG in ischemic cardiomyopathy](https://reader034.fdocuments.in/reader034/viewer/2022052316/559426a71a28ab1f768b47a6/html5/thumbnails/9.jpg)
1. Significant left main disease
2. Left main equivalent disease ( ≥ 70 % stenosis of proximal LAD and Proximal LCX)
3. Proximal LAD stenosis with two or three vessel disease
![Page 10: CABG in ischemic cardiomyopathy](https://reader034.fdocuments.in/reader034/viewer/2022052316/559426a71a28ab1f768b47a6/html5/thumbnails/10.jpg)
Coronary-Artery Bypass Surgery in Patients with Left Ventricular
Dysfunction(STICH trial)
![Page 11: CABG in ischemic cardiomyopathy](https://reader034.fdocuments.in/reader034/viewer/2022052316/559426a71a28ab1f768b47a6/html5/thumbnails/11.jpg)
STICH = Surgical Treatment for Ischemic Heart Failure
![Page 12: CABG in ischemic cardiomyopathy](https://reader034.fdocuments.in/reader034/viewer/2022052316/559426a71a28ab1f768b47a6/html5/thumbnails/12.jpg)
Methods
![Page 13: CABG in ischemic cardiomyopathy](https://reader034.fdocuments.in/reader034/viewer/2022052316/559426a71a28ab1f768b47a6/html5/thumbnails/13.jpg)
Study Design
• Non-blinded, Randomized study.
• Sponsored by NHLBI and Abbott Laboratories
• Design to have 90% power to detect a 25% reduction in mortality with CABG as compared with medical therapy alone
![Page 14: CABG in ischemic cardiomyopathy](https://reader034.fdocuments.in/reader034/viewer/2022052316/559426a71a28ab1f768b47a6/html5/thumbnails/14.jpg)
Study Patients
• CAD amenable to CABG
• EF of 35% or less
![Page 15: CABG in ischemic cardiomyopathy](https://reader034.fdocuments.in/reader034/viewer/2022052316/559426a71a28ab1f768b47a6/html5/thumbnails/15.jpg)
Study Procedures
• CABG is performed by cardiac surgeon in whom have operative death rate less than 5%
• Patients are followed at 30 days, every 4 months then every 6 months on next year
![Page 16: CABG in ischemic cardiomyopathy](https://reader034.fdocuments.in/reader034/viewer/2022052316/559426a71a28ab1f768b47a6/html5/thumbnails/16.jpg)
Primary Outcome
• Rate of death from any cause
![Page 17: CABG in ischemic cardiomyopathy](https://reader034.fdocuments.in/reader034/viewer/2022052316/559426a71a28ab1f768b47a6/html5/thumbnails/17.jpg)
Secondary Outcome
• “Rate of death from CVS cause”
• “Rate of death from any cause or hospitalization from cardiovascular cause”
![Page 18: CABG in ischemic cardiomyopathy](https://reader034.fdocuments.in/reader034/viewer/2022052316/559426a71a28ab1f768b47a6/html5/thumbnails/18.jpg)
Statistical Analysis
• Intention to treat analysis
• Kaplan Meier method
• As treated analysis
![Page 19: CABG in ischemic cardiomyopathy](https://reader034.fdocuments.in/reader034/viewer/2022052316/559426a71a28ab1f768b47a6/html5/thumbnails/19.jpg)
Result
![Page 20: CABG in ischemic cardiomyopathy](https://reader034.fdocuments.in/reader034/viewer/2022052316/559426a71a28ab1f768b47a6/html5/thumbnails/20.jpg)
Study Population
• 1212 Patients from 22 countries
• 602 has medial therapy
• 610 has CABG + Medical Therapy
![Page 21: CABG in ischemic cardiomyopathy](https://reader034.fdocuments.in/reader034/viewer/2022052316/559426a71a28ab1f768b47a6/html5/thumbnails/21.jpg)
CABG group610 Patients
529 (95%) got surgery
63 also got mitral valve
repair
Medical Group602 Patients
100 (17%) end up getting surgery
1. Progressive symptoms2. Acute decompensation3. Family ‘s decision4. Physician’s decision
![Page 22: CABG in ischemic cardiomyopathy](https://reader034.fdocuments.in/reader034/viewer/2022052316/559426a71a28ab1f768b47a6/html5/thumbnails/22.jpg)
Follow-up
• 5 of 1212 patients were loss to follow up.
• Median length of follow-up is 56 months
![Page 23: CABG in ischemic cardiomyopathy](https://reader034.fdocuments.in/reader034/viewer/2022052316/559426a71a28ab1f768b47a6/html5/thumbnails/23.jpg)
Outcome Medical Therapy CABG
Rate of death from any cause
41 % 36 %
Primary Outcome
Hazard Ratio with CABG 0.86 P Value 0.12
![Page 24: CABG in ischemic cardiomyopathy](https://reader034.fdocuments.in/reader034/viewer/2022052316/559426a71a28ab1f768b47a6/html5/thumbnails/24.jpg)
![Page 25: CABG in ischemic cardiomyopathy](https://reader034.fdocuments.in/reader034/viewer/2022052316/559426a71a28ab1f768b47a6/html5/thumbnails/25.jpg)
Secondary Outcome
Outcome Medical Therapy CABG Hazard Ratio
Death from cardiovascular
cause33 % 28 %
0.81(0.66-1.00)
Death from any cause or admit for
HF54 % 48 %
0.84(0.71-0.98)
![Page 26: CABG in ischemic cardiomyopathy](https://reader034.fdocuments.in/reader034/viewer/2022052316/559426a71a28ab1f768b47a6/html5/thumbnails/26.jpg)
![Page 27: CABG in ischemic cardiomyopathy](https://reader034.fdocuments.in/reader034/viewer/2022052316/559426a71a28ab1f768b47a6/html5/thumbnails/27.jpg)
![Page 28: CABG in ischemic cardiomyopathy](https://reader034.fdocuments.in/reader034/viewer/2022052316/559426a71a28ab1f768b47a6/html5/thumbnails/28.jpg)
As-treated analysis
CABG620 Patients
including cross over
Medical Management592 Patients
![Page 29: CABG in ischemic cardiomyopathy](https://reader034.fdocuments.in/reader034/viewer/2022052316/559426a71a28ab1f768b47a6/html5/thumbnails/29.jpg)
As-treated analysis
![Page 30: CABG in ischemic cardiomyopathy](https://reader034.fdocuments.in/reader034/viewer/2022052316/559426a71a28ab1f768b47a6/html5/thumbnails/30.jpg)
Limitations
• Non blinded study has an effect on non fatal outcome
• Trial was design to detect 25% reduction in mortality with CABG
• Limited power and limited duration of follow-up